LabGenius
Using the genius of AI to fight cancer O
ne in two people will be diagnosed with cancer in their lifetime. That’s half of us. Cancer is a leading cause of death worldwide and the second most common cause of death in the U.S. But as the saying goes, sometimes the cure is worse than the disease. Chemotherapy and radiation, the first-line treatments for cancer, take a nuclear approach, obliterating healthy cells along with cancerous ones. Even then, these treatments often don’t successfully kill all cancer cells, leading to resistance and relapse in patients.
50
So how do you develop new therapeutics that target cancer and leave healthy cells unharmed? This is what LabGenius is here to answer. Based in South East London, LabGenius is a team of drug hunters, robotic automation experts, data scientists, and software engineers focused on discovering new protein therapeutics using artificial intelligence. Protein therapeutics represent a massive category within the pharmaceutical industry. Seven of the top 10 best-selling drugs today are protein therapeutics. And around 25% of the $1.4 trillion in global pharmaceutical sales are biologics, which include protein therapy, gene therapy, and cell therapy. The team at LabGenius is focused on developing new antibodybased proteins to treat solid cancerous tumors—which account for 90% of all adult cancer cases. Discovering new antibodies is challenging because only a small number have the potential to make effective therapeutics.